Drugs in the Pipeline
GTx announced the continuation clinical development as planned with its two pivotal Phase 3 trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.
Drugs in the Pipeline
Nereus Pharmaceuticals announced that it is conducting a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) NPI-2358.
Drugs in the Pipeline
Merck announced that the KEYNOTE-010 study of Keytruda (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) met its primary endpoint.
Drugs in the Pipeline
AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an investigational combination with chemotherapies or radiation for the treatment of advanced squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
The FDA has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for Xalkori (crizotinib; Pfizer).
Drugs in the Pipeline
Synta announced results from its Phase 2 study of ganetespib (STA-9090) for the treatment of NSCLC.
Drugs in the Pipeline
Pfizer announced results from PROFILE 1014, a Phase 3 study of Xalkori (crizotinib) in previously untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
Lilly announced new data from two Phase 2 ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
AbbVie announced the initiation of a Phase 3 trial evaluating the safety and efficacy of veliparib (ABT-888) in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
Tragara announced the completion of patient enrollment to its APRiCOT-L study, a Phase 2 trial of its anti-cancer agent, Capoxigem (apricoxib, TG01), in non-small cell lung cancer (NSCLC).
